MC
AERI

Maverick Capital’s Aerie Pharmaceuticals AERI Stock Holding History

Maverick Capital’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,723
Closed -$77K – 665
2021
Q3 		$77K Sell
6,723
-28,534
-81% -$417K ﹤0.01% 601
2021
Q2 		$564K Sell
35,257
-3,269
-8% -$56.1K 0.01% 372
2021
Q1 		$688K Buy
38,526
+21,946
+132% +$379K 0.01% 342
2020
Q4 		$224K Buy
+16,580
New +$200K ﹤0.01% 511

Other funds holding AERI

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Maverick Capital's AERI Position: Q4 2021 in Review

Maverick Capital sold out of Aerie Pharmaceuticals (AERI) in Q4 2021, closing a stake of 6,723 shares — an estimated $77K sold.

Maverick Capital first reported a position in AERI in Q4 2020 and held it in 4 quarters. The position peaked at $688K in Q1 2021. 129 funds tracked by Wall St. Rank hold AERI as of Q4 2021.

  • Maverick Capital reported no remaining Aerie Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Maverick Capital sold 6,723 Aerie Pharmaceuticals shares in Q4 2021, an estimated $77K.
  • Maverick Capital first reported a position in Aerie Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Maverick Capital's Aerie Pharmaceuticals position peaked at $688K in Q1 2021.
  • 129 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2021.

Based on Maverick Capital's 13F filing for Q4 2021, filed 14 Feb 2022.